Researchers at UC Davis Comprehensive Cancer Center and Indiana University School of Medicine have made a significant breakthrough in cancer treatment. They discovered that CD95, or Fas receptors, can trigger a natural process of programmed cell death. This opens the possibility to target a specific part of the Fas receptor that initiates cell death, potentially turning the tide against solid tumors and resistant cancers. The capability of CD95 receptors to initiate programmed cell death underscores the necessity to create drugs that increase death receptor activity. This is especially promising for solid tumors, difficult to treat with immunotherapies like CAR T-cell therapy. Fas receptors could possibly instigate a CAR-T bystander effect, annihilating not only targeted cancer cells but those lacking the targeted molecule. This could revolutionize treatment of genetically diverse tumors, providing a solution to overcome therapy resistance.
Full article here: https://lawsuithelpdesk.com/unlocking-a-death-sentence-for-cancer-the-potential-game-changer-in-car-t-cell-therapy/